Skip To Main Content
Qiaoxian Yin on Muck Rack

Qiaoxian Yin

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Qiaoxian

Contact Qiaoxian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial

|
By Lin Zhou, Jing Zhao, Sijian Li, Dongqin Zhu, Yin Wang, Xiaoliu Wu, Hongying Yang, Wenyan Wang, Xin Huang, Chunyan Lan, Haixi Liang, Qiaoxian Yin, Xielan Yang
| Nature Verified
Abstract Treatment options are limited for women with advanced endometrial cancer after platinum-based chemotherapy. In this single-arm, multicenter phase II CLEAR-EC trial with a safety run-in, we evaluated cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus lenvatinib as second-line or later therapy (ClinicalTrials.gov: NCT05824481). Three patients were enrolled in the safety run-in, followed by 29 additional patients after the recommended phase II dose was established.
Open in Who Shared Issue with article?
See all 1 articles